Thursday, July 7, 2011

Nasal Type 1 Diabetes Spray Vaccine: Pharma Int. News

Nasal Type 1 Diabetes Spray Vaccine: Pharma Int. News

Australian researchers have developed a pioneering inhaled spray product designed to stop the onset of type 1 diabetes.
The diabetes prevention spray vaccine's presently being put through clinical trials and it's already produced positive results from mouse-based trials. 52 participants, all aged over 18, are taking part and all have early-stage type 1 diabetes.
Type 1 diabetes takes place when the immune system turns on the beta cells responsible for manufacturing insulin and, as a result, glucose levels in urine and blood surge. Type 1 diabetes patients are therefore generally prescribed a daily supply of insulin via injection, to bring glucose levels back down.
While the Type 1 Diabetes Prevention Trial participants all entered it with pre-existing diabetes, they didn't yet require daily insulin, so they were they divided into two groups.

Nasal Spray Vaccine

The first group was administered with the nasal spray vaccine, while the second acted as a control group and was given a placebo, instead. In both instances, those involved were given a 12-month supply and monitored continually throughout.
"The results showed that the vaccine allowed the immune system to restore immune tolerance
to insulin", Professor Len Harrison, representing Melbourne's Walter and Eliza Hall Institute - one of two institutions involved, alongside the Royal Melbourne Hospital - explained, adding: "When subsequently given insulin by injection, the participants who had received the nasal insulin vaccine were found to be desensitized to insulin.
"The nasal vaccine approach, if shown to be successful in human type 1 diabetes, could also be tested with different vaccines for the prevention of other autoimmune diseases such as rheumatoid arthritis and multiple sclerosis."

No comments:

Post a Comment